Diabetic Neuropathy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Diabetic Neuropathy – Pipeline Review, H1 2017’, provides an overview of the Diabetic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy

– The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Angelini Group

Apollo Endosurgery Inc

Araim Pharmaceuticals Inc

Celgene Corp

Commence Bio Inc

Grunenthal GmbH

Kineta Inc

KPI Therapeutics Inc

Medifron DBT Co Ltd

Neuralstem Inc

NovaLead Pharma Pvt Ltd

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

ViroMed Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Neuropathy - Overview

Diabetic Neuropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Neuropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Neuropathy - Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Angelini Group

Apollo Endosurgery Inc

Araim Pharmaceuticals Inc

Celgene Corp

Commence Bio Inc

Grunenthal GmbH

Kineta Inc

KPI Therapeutics Inc

Medifron DBT Co Ltd

Neuralstem Inc

NovaLead Pharma Pvt Ltd

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

ViroMed Co Ltd

Diabetic Neuropathy - Drug Profiles

A-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAD-2004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atexakin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNV-222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cibinetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-2197944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyndacel-M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCP-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-32 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lpathomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-566 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-721 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTA-901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Diabetic Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trazodone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XK-568b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Neuropathy - Dormant Projects

Diabetic Neuropathy - Discontinued Products

Diabetic Neuropathy - Product Development Milestones

Featured News & Press Releases

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition

Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab

Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Diabetic Neuropathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Diabetic Neuropathy – Pipeline by Achelios Therapeutics Inc, H1 2017

Diabetic Neuropathy – Pipeline by Angelini Group, H1 2017

Diabetic Neuropathy – Pipeline by Apollo Endosurgery Inc, H1 2017

Diabetic Neuropathy – Pipeline by Araim Pharmaceuticals Inc, H1 2017

Diabetic Neuropathy – Pipeline by Celgene Corp, H1 2017

Diabetic Neuropathy – Pipeline by Commence Bio Inc, H1 2017

Diabetic Neuropathy – Pipeline by Grunenthal GmbH, H1 2017

Diabetic Neuropathy – Pipeline by Kineta Inc, H1 2017

Diabetic Neuropathy – Pipeline by KPI Therapeutics Inc, H1 2017

Diabetic Neuropathy – Pipeline by Medifron DBT Co Ltd, H1 2017

Diabetic Neuropathy – Pipeline by Neuralstem Inc, H1 2017

Diabetic Neuropathy – Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Diabetic Neuropathy – Pipeline by Omeros Corp, H1 2017

Diabetic Neuropathy – Pipeline by Reata Pharmaceuticals Inc, H1 2017

Diabetic Neuropathy – Pipeline by Relief Therapeutics Holding AG, H1 2017

Diabetic Neuropathy – Pipeline by ViroMed Co Ltd, H1 2017

Diabetic Neuropathy – Dormant Projects, H1 2017

Diabetic Neuropathy – Dormant Projects, H1 2017 (Contd..1), H1 2017

Diabetic Neuropathy – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Neuropathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports